-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

LEO Pharma and ICON Ink Deal to Propel Clinical Trial Execution Within Medical Dermatology

Benzinga · 03/10/2023 02:33

LEO Pharma, a global leader in medical dermatology, and ICON plc (NASDAQ:ICLR) today announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective, and which will support the company's overall ambition of building one of the most effective and efficient clinical portfolio execution organisations in the industry.